Dapagliflozin After Transcatheter Aortic Valve Implantation
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
Pragmatic, controlled, prospective, randomized, open-label (open-label), evaluator-blind
clinical trial (PROBE design) that will analyze the benefits of dapagliflozin treatment in
patients with severe aortic stenosis discharged after implantation of an aortic valve
prosthesis transcatheter (TAVI).
Phase:
Phase 4
Details
Lead Sponsor:
Spanish Society of Cardiology
Collaborator:
Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III